INMB Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.265

Open

1.225

VWAP

1.23

Vol

111.72K

Mkt Cap

32.97M

Low

1.200

Amount

137.81K

EV/EBITDA(TTM)

--

Total Shares

26.59M

EV

5.23M

EV/OCF(TTM)

--

P/S(TTM)

586.68

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Show More

Events Timeline

(ET)

2026-02-12

07:20:00

INmune Bio Receives FDA Meeting Minutes on XPro1595

2026-02-10 (ET)

2026-02-10

08:10:00

INmune Bio Submits Pre-Submission Package for CORDStrom

2026-01-27 (ET)

2026-01-27

09:30:00

INmune Bio CEO Thanks Investors, Looks Ahead to 2025

2025-12-05 (ET)

2025-12-05

07:10:00

INmune Bio Publishes Overview of Future Applications for MSC Therapies

2025-12-01 (ET)

2025-12-01

08:20:00

INmune Bio Reveals New Neuroimaging Data Showing XPro1595 Slows Alzheimer's Progression

2025-10-30 (ET)

2025-10-30

16:41:03

INmune Bio announces Q3 earnings per share of 24 cents, below consensus estimate of 32 cents.

2025-09-29 (ET)

2025-09-29

08:19:51

INmune Bio presents Phase 2 MINDFuL trial findings to npj Dementia

2025-09-15 (ET)

2025-09-15

08:08:39

INmune Bio Successfully Finishes Initial Commercial Production of CORDStrom

News

Newsfilter

02-23Newsfilter

INmune Bio Hosts Webinar on Alzheimer's Treatment Pathway

Newsfilter

02-19Newsfilter

INmune Bio to Host CORDStrom Webinar on RDEB Treatment

stocktwits

02-12stocktwits

INmune Bio Receives FDA Support for Alzheimer’s Therapy

Globenewswire

2025-12-05Globenewswire

INmune Bio Publishes Overview on Future Applications of MSC Therapies

Globenewswire

2025-12-01Globenewswire

INmune Bio Presents New XPro1595 Data for Alzheimer's Disease at CTAD

Newsfilter

2025-09-15Newsfilter

INmune Bio Successfully Completes Initial Commercial Pilot-Scale Production of CORDStrom™ at CGT Catapult

2 Analyst Rating

Wall Street analysts forecast INMB stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Lucid Capital

Lucid Capital

Neutral -> Buy

upgrade

$2 -> $9

AI Analysis

2026-03-11

Reason

Lucid Capital

Lucid Capital

Price Target

$2 -> $9

AI Analysis

2026-03-11

upgrade

Neutral -> Buy

Reason

Lucid Capital upgraded INmune Bio to Buy from Neutral with a price target of $9, up from $2. The firm is now factoring into the model the company's CORDStrom therapy for recessive dystrophic epidermolysis bullosa. Lucid cites the expanded scope of value drivers across INmune's pipeline for the upgrade.

Alliance Global Partners

Buy

downgrade

$20 -> $7

2025-07-03

Reason

Alliance Global Partners

Price Target

$20 -> $7

2025-07-03

downgrade

Buy

Reason

Alliance Global Partners lowered the firm's price target on INmune Bio to $7 from $20 and keeps a Buy rating on the shares after the company reported topline Phase 2 data from the MINDful trial of XPro for Alzheimer's disease that "were not what we had hoped for." The firm adjusted its price target to account for the added uncertainly around the future development for XPro and the additional time that will be needed to find a partner and start confirmatory trials, noting that it now values XPro for Alzheimer's at $3 per share.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INMB

Unlock Now

Valuation Metrics

The current forward P/E ratio for INmune Bio Inc (INMB.O) is -1.30, compared to its 5-year average forward P/E of -4.47. For a more detailed relative valuation and DCF analysis to assess INmune Bio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.47

Current PE

-1.30

Overvalued PE

-2.40

Undervalued PE

-6.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

1351.00

Current PS

0.00

Overvalued PS

3906.98

Undervalued PS

-1204.98

Financials

AI Analysis

Annual

Quarterly

Whales Holding INMB

Trading Trends

People Also Watch

Frequently Asked Questions

What is INmune Bio Inc (INMB) stock price today?

The current price of INMB is 1.2357 USD — it has decreased -0.32

What is INmune Bio Inc (INMB)'s business?

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

What is the price predicton of INMB Stock?

Wall Street analysts forecast INMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMB is8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is INmune Bio Inc (INMB)'s revenue for the last quarter?

INmune Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is INmune Bio Inc (INMB)'s earnings per share (EPS) for the last quarter?

INmune Bio Inc. EPS for the last quarter amounts to -0.24 USD, decreased -60.00

How many employees does INmune Bio Inc (INMB). have?

INmune Bio Inc (INMB) has 22 emplpoyees as of March 19 2026.

What is INmune Bio Inc (INMB) market cap?

Today INMB has the market capitalization of 32.97M USD.